Mr Alan Charles Needham, MA, CCC-A | |
4 Northwestern Dr, Bloomfield, CT 06002-3444 | |
(860) 243-9510 | |
Not Available |
Full Name | Mr Alan Charles Needham |
---|---|
Gender | Male |
Speciality | Hearing Aid Equipment |
Location | 4 Northwestern Dr, Bloomfield, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356400881 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Mr Alan Charles Needham, MA, CCC-A 4 Northwestern Dr, Bloomfield, CT 06002-3444 Ph: (860) 243-9510 | Mr Alan Charles Needham, MA, CCC-A 4 Northwestern Dr, Bloomfield, CT 06002-3444 Ph: (860) 243-9510 |
News Archive
With the growing demands of consumerism and the need to assist customers on the clock, today's employees are working anything but nine to five.
Our state of arousal-being fearful, agitated, or calm-can significantly affect our ability to make optimal decisions, judgments, and actions in real-world dynamic environments. Imagine, for instance, walking across a balance beam.
Beckman Coulter announced the results of a prospective study carried out across two European hospitals, which found that Monocyte Distribution Width, in combination with White Blood Cell Count with Differential, has the diagnostic accuracy to detect the risk of sepsis and severe infection upon patient presentation in A&E, particularly when assessed in patients with a lower likelihood of sepsis.
Dassault Systèmes, the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, announced today that Ion Beam Applications SA, the leading medical device manufacturer and pioneer in proton beam therapy for cancer treatment, selected the 3DEXPERIENCE platform based on V6 architecture, and its "Licensed to Cure for Medical Device" industry solution experience.
Apricus Biosciences, Inc., backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.
› Verified 2 days ago